Effects of immunoregulatory cytokines on the immunogenic potential of the cellular components of a bilayered living skin equivalent.
The purpose of this study was to determine if the immunocompatibility of an allogeneic living skin equivalent (LSE) would be affected by cytokines that would be potentially present at the wound site. Specifically, the ability of interleukin-1alpha (IL-1a), interleukin-6 (IL-6), or interleukin-12 (IL-12) to induce an allogeneic T cell response to "nonprofessional" antigen presenting cells (APC) was investigated in this series of experiments. Since cytokine concentrations at the wound site can vary greatly, recombinant IL-1a, IL-6, and IL-12 were used over a wide range of concentrations. These cytokines were either added directly to a mixed lymphocyte reaction (MLR) culture system or used to pretreat APC prior to use in the MLR culture. The addition of IL-12, IL-1alpha, or IL-6 into an MLR was examined as a possible means of providing the necessary costimulatory signal for functionally deficient APC, such as human keratinocytes (HK) and dermal fibroblasts (HF). While the results show that IL-1a and IL-12 can significantly augment a primary allogeneic response against appropriately equipped antigen presenting cells, the same was not true for HK or HF. Further experiments showed that pretreatment of HK, HF, or human umbilical vein endothelial cells (HUVEC) with Interferon-gamma (IFNgamma) and either IL-12, IL1alpha, or IL-6 had no significant affect on their ability to present alloantigen to immune-reactive T lymphocytes over IFNgamma-treatment alone. The data suggest that exposure of HK or HF to IL-1alpha, IL-6, or IL-12 in combination with IFNgamma does not provide the additional signal(s) required by these cells to effectively present alloantigen to unprimed T cells. The data suggests that exposure to these immunoregulatory cytokines in the wound bed would be unlikely to affect the immunocompatibility of the LSE.
Laning
J C
JC
Research and Development, Division of Immunology and Transplantation Sciences, Organogenesis, Inc., Canton, Massachusetts 02021, USA. jlaning@organo.com
DeLuca
J E
JE
Hardin-Young
J
J
D000938:Antigen-Presenting Cells / Q000276:immunology; D002478:Cells, Cultured; D016207:Cytokines / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D005347:Fibroblasts / Q000166:cytology; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D007375:Interleukin-1 / Q000235:genetics / Q000494:pharmacology; D018664:Interleukin-12 / Q000494:pharmacology; D015850:Interleukin-6 / Q000235:genetics / Q000494:pharmacology; D015603:Keratinocytes / Q000166:cytology*; D007959:Lymphocyte Culture Test, Mixed; D011994:Recombinant Proteins / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012867:Skin / Q000166:cytology* / Q000187:drug effects / Q000276:immunology*; D017768:Skin, Artificial; D013601:T-Lymphocytes / Q000276:immunology; D014471:Umbilical Veins
D016207:Cytokines; D007375:Interleukin-1; D015850:Interleukin-6; D011994:Recombinant Proteins; D018664:Interleukin-12; D007371:Interferon-gamma